>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

1.43 0.03 (2.14%) 10/02/2026
Cellectis S.A. (CLLS)
Performance
Historical returns
1D
2.14%
1W
-3.38%
1M
-56.00%
3M
-56.67%
6M
-58.06%
1Y
-58.19%
5Y
-88.25%
Snapshot
Key statistics
Close
1.43
Change
0.03
Change %
2.14%
Open
1.45
Day Range
1.42 – 1.47
Volume
46,727
Avg Vol (20d)
208,251
Rel Vol
0.22x
52W Range
1.25 - 5.48
vs 52W High
-73.91%
vs 52W Low
14.40%
Gap
-0.05
Market Cap
USD 143.60M
Beta
3.11
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Create a free account
Bull vs Bear
2 bullish · 8 bearish points
Bullish view
  • FY2025 earnings rose 83.9% to -$67.59M.
  • The Aug 2026 quarter beat on EPS by $0.04 (16.3% above consensus).
Bearish view
  • Operating margin compressed to -449.8% in the Jun 2026 quarter from -57.3% a year earlier.
  • Gross margin slipped to 55.0% from 85.5% a year ago.
  • Revenue fell 68.7% year on year in the Jun 2026 quarter.
  • Missed consensus EPS in 4 of the last 8 quarters.
  • Revenue in the same quarter came in $4.15M short of consensus.
  • Trades 58.0% below its 200-day average, a downtrend still intact.
  • Still 73.3% below its 52-week high of $5.35.
  • Lagged the S&P 500 by 59.0% over the last quarter (-56.5% against +2.4%).
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Oct 2
2026
$1.43 2.14%Latest
Cellectis rose 2.14% to $1.43, though on light volume (0.2× the 20-day average). The move was broadly in line with the wider market — the S&P 500 gained 0.74% while Healthcare peers (XLV) fell 0.01% the same session — so little of it was company-specific. Shares opened with a 3.57% gap up and closed near the session low (20% of the day's range). The move left the stock 73.3% below its 52-week high.
Sep 17
2026
$1.46 6.18%
Cellectis rose 6.18% to $1.46, its biggest one-day gain in 3 weeks, on 2.3× average volume. The move was broadly in line with the wider market — the S&P 500 gained 1.39% while Healthcare peers (XLV) rose 0.62% the same session — so little of it was company-specific. Shares opened with a 5.45% gap up.
Sep 16
2026
$1.38 14.60%52W Low
Cellectis fell 14.60% to $1.38, a 2.2σ move against its 60-day volatility, on 5.8× average volume. This was largely stock-specific: the S&P 500 fell 0.44% while Healthcare peers (XLV) rose 0.07% that session, leaving about 13.2 points of the move unexplained by the market after adjusting for a 3.11 beta. Shares opened with an 11.18% gap down, set a 52-week closing low and marked a 8th consecutive decline.
Sep 15
2026
$1.61 12.02%52W Low
Cellectis fell 12.02% to $1.61, a 1.8σ move against its 60-day volatility, on 10.1× average volume. This was largely stock-specific: the S&P 500 fell 0.46% while Healthcare peers (XLV) fell 0.05% that session, leaving about 10.6 points of the move unexplained by the market after adjusting for a 3.11 beta. Shares opened with a 9.84% gap down, set a 52-week closing low and marked a 7th consecutive decline.
Sep 14
2026
$1.83 40.97%52W Low
Cellectis fell 40.97% to $1.83, its biggest one-day drop in 3.1 years and a 10.8σ move against its 60-day volatility, on 56.9× average volume. This was largely stock-specific: the S&P 500 fell 0.45% while Healthcare peers (XLV) rose 1.45% that session, leaving about 39.6 points of the move unexplained by the market after adjusting for a 3.11 beta. Shares opened with a 25.16% gap down, closed near the session low (11% of the day's range), lost their 50-day moving average, set a 52-week closing low and marked a 6th consecutive decline. The move erased $127.8M of market value.
Sep 8
2026
$3.16 2.47%
Cellectis fell 2.47% to $3.16, on 2.3× average volume. The move was broadly in line with its sector — the S&P 500 fell 0.55% while Healthcare peers (XLV) fell 2.52% the same session — so little of it was company-specific. Shares closed near the session low (0% of the day's range) and lost their 20-day moving average.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month1.25 +14.40%
on 09/16/26
Open 3.25
3.45 -58.49%
on 09/03/26
-1.82 (-56.00%)
since 09/02/26
3-Month1.25 +14.40%
on 09/16/26
Open 3.29
3.60 -60.28%
on 08/27/26
-1.86 (-56.53%)
since 07/06/26
6-Month1.25 +14.40%
on 09/16/26
Open 3.41
4.55 -68.57%
on 04/13/26
-1.98 (-58.06%)
since 04/02/26
YTD1.25 +14.40%
on 09/16/26
Open 4.80
4.97 -71.23%
on 01/02/26
-3.37 (-70.21%)
since 01/02/26
52-Week1.25 +14.40%
on 09/16/26
Open 3.29
5.48 -73.91%
on 10/16/25
-1.86 (-56.53%)
since 10/01/25
5-Year0.96 +49.27%
on 10/26/23
Open 13.41
13.93 -89.73%
on 09/24/21
-11.98 (-89.34%)
since 09/24/21
New Highs
Historical highs
5-Day
1×
-5.30% from peak
1-Month
0×
-56.93% from peak
3-Month
2×
-59.77% from peak
6-Month
4×
-67.65% from peak
YTD
0×
-70.21% from peak
52-Week
8×
-73.27% from peak
2-Year
17×
-73.27% from peak
3-Year
15×
-73.27% from peak
5-Year
0×
-89.42% from peak
10-Year
12×
-96.29% from peak
Financial SnapshotFY 2025
Full financials
Revenue
USD 75.92M
+82.9% YoY
Net Income
-USD 67.59M
+83.9% YoY
EPS
-0.70
+70.7% YoY
Gross Margin
72.5%
Operating Margin
-55.3%
Net Margin
-89.0%
EBITDA
-USD 21.12M
Free Cash Flow
-USD 44.10M
-58.1% margin
ROE
-89.0%
ROA
-20.8%
Debt / Equity
1.20x
net debt USD 29.20M
Cash & Equiv.
USD 61.53M
News
All news
10/01 16:02 ET · marketbeat.com
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
Cellectis NASDAQ: CLLS outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through one-time intravenous treatments.
10/01 10:00 ET · prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
09/30 06:28 ET · defenseworld.net
Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Price Target of $5.46
Cellectis S.A. (NASDAQ: CLLS - Get Free Report) has received an average rating of "Hold" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, two have given a buy...
09/29 17:32 ET · globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
09/19 20:00 ET · gurufocus.com
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
09/17 14:45 ET · globenewswire.com
CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC
ATLANTA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) complied with federal securities laws. On September 14, 2026, Cellectis announced that it will “exit the development of lasme-cel and...
09/17 11:00 ET · gurufocus.com
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf
09/17 11:00 ET · businesswire.com
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) investors concerning the Company's possible...

Market News ×
Loading news…